- Home
- PRTA
as 11-15-2024 4:00pm EST
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
| Founded: | 2012 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 802.8M | IPO Year: | N/A |
| Target Price: | $57.67 | AVG Volume (30 days): | 476.3K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.00 - $41.55 | Next Earning Date: | 11-12-2024 |
| Revenue: | $133,350,000 | Revenue Growth: | -5.41% |
| Revenue Growth (this year): | 60.63% | Revenue Growth (next year): | -38.64% |
Latest Prothena Corporation plc News
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
Zacks
4 days ago
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
Zacks
4 days ago
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
Associated Press Finance
4 days ago
Prothena: Q3 Earnings Snapshot
Business Wire
4 days ago
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
Zacks
6 days ago
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Business Wire
11 days ago
Prothena to Report Third Quarter 2024 Financial Results on November 12
Zacks
19 days ago
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
Compare PRTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.